InvestorLens

APLS — APELLIS PHARMACEUTICALS INC

Public company

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying APLS?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
80
Institutional Conviction
Net accumulation · 4 buying vs 1 selling last quarter
66
Macro Tailwind
Macro conditions are mixed for this sector
52
Why? — Evidence & Confidence ▾

Of 5 tracked investors who changed their APLS position last quarter, 4 bought and 1 sold (80% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Squeeze regime).

Supporting evidence
  • +4 tracked investors added or increased positions last quarter (Izzy Englander, Ken Griffin, Steve Cohen, …)
  • +5 tracked investors reported holding APLS at their latest filing
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About APELLIS PHARMACEUTICALS INC (APLS)

APELLIS PHARMACEUTICALS INC (APLS) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $168M. Across recent filings, tracked investors recorded 8 new positions, 0 increased, 1 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in APLS

89
/100
Strong Institutional Accumulation
Added / Increased8
Reduced1
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track APLS

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

APLS Ownership Composition

How APELLIS PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Hedge Funds
67% of tracked value
Institutions
5
tracked investors
Total Reported
$313.9M
combined 13F value
Sectors2
  • Hedge Funds67.1%
  • Other32.9%
Hedge Funds(2)
67.1%
Other(3)
32.9%

Tracked investors reporting APLS

  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    4.2M
    Value
    $168.3M
    % Portfolio
    0.22%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    2.3M
    Value
    $91.1M
    % Portfolio
    0.04%
  • George SorosMar 31, 2026
    Soros Fund Management
    Shares
    1.1M
    Value
    $42.5M
    % Portfolio
    0.47%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    263.3K
    Value
    $10.6M
    % Portfolio
    0.00%
  • Ray DalioMar 31, 2026
    Bridgewater Associates
    Shares
    34.9K
    Value
    $1.4M
    % Portfolio
    0.01%

Recent activity

Frequently asked questions

How many institutional investors hold APLS?
5 tracked institutional investors disclosed a position in APLS (APELLIS PHARMACEUTICALS INC) in their most recent 13F filing.
Who is the largest institutional holder of APLS?
Steve Cohen, Point72 Asset Management, holds the largest disclosed position in APLS, valued at $168M.
Did institutional ownership of APLS increase or decrease?
Across recent 13F filings, tracked investors recorded 8 new positions, 0 increased, 1 reduced, and 0 fully exited APLS.
Where does this APLS ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.